var data={"title":"Pathogenesis of atherosclerosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pathogenesis of atherosclerosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/contributors\" class=\"contributor contributor_credentials\">Xue-Qiao Zhao, MD, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/contributors\" class=\"contributor contributor_credentials\">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/contributors\" class=\"contributor contributor_credentials\">Peter Libby, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/contributors\" class=\"contributor contributor_credentials\">Gordon M Saperia, MD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 09, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H27901057\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Atherosclerosis is a pathologic process that causes disease of the coronary, cerebral, and peripheral arteries and the aorta [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Forms of accelerated arteriopathies, such as restenosis following percutaneous coronary intervention with stenting and coronary transplant vasculopathy differ in pathogenesis and are discussed separately. (See <a href=\"topic.htm?path=intracoronary-stent-restenosis\" class=\"medical medical_review\">&quot;Intracoronary stent restenosis&quot;</a> and <a href=\"topic.htm?path=pathogenesis-of-and-risk-factors-for-cardiac-allograft-vasculopathy\" class=\"medical medical_review\">&quot;Pathogenesis of and risk factors for cardiac allograft vasculopathy&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H27901064\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Atherosclerosis can begin in childhood with the development of fatty streaks (<a href=\"image.htm?imageKey=CARD%2F56922\" class=\"graphic graphic_table graphicRef56922 \">table 1</a>). The lesions of atherosclerosis advance with aging [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/3-5\" class=\"abstract_t\">3-5</a>]. The following points demonstrate the frequency of atherosclerosis in Western populations and its progression with age:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In an autopsy study of 2876 men and women aged 15 to 34 years who died of non-cardiac causes, all individuals had aortic fatty streaks [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/6\" class=\"abstract_t\">6</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another autopsy study of 760 young (age 15 to 34 years) victims of accidents, suicides, or homicides, advanced coronary atheromata were seen in 2 and 0 percent of men and women aged 15 to 19, and 20 and 8 percent of men and women aged 30 to 34 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/5\" class=\"abstract_t\">5</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study of 260 peri-renal aortic patches collected during organ transplantation, the first three decades of life were characterized by intimal thickening and xanthomas. The fourth, fifth, and sixth decades were characterized by more complicated plaques of pathological intimal thickening, early and late fibroatheromas with thin fibrous caps, ruptured plaques, healed rupture, and fibrotic calcified plaques [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/7\" class=\"abstract_t\">7</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Using intracoronary ultrasound, one in six United States teenagers have abnormal intimal thickening [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/4\" class=\"abstract_t\">4</a>]. </p><p/><p class=\"headingAnchor\" id=\"H41092387\"><span class=\"h1\">HISTOLOGY</span></p><p class=\"headingAnchor\" id=\"H27901080\"><span class=\"h2\">Fatty streaks</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The first phase in atherosclerosis histologically occurs as focal thickening of the intima with accumulation of lipid-laden macrophages (foam cells) and extracellular matrix (<a href=\"image.htm?imageKey=CARD%2F56922\" class=\"graphic graphic_table graphicRef56922 \">table 1</a> and <a href=\"image.htm?imageKey=CARD%2F76466\" class=\"graphic graphic_figure graphicRef76466 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/8\" class=\"abstract_t\">8</a>]. Smooth muscle cells can also populate the intima, some of which may arise from hematopoietic stem cells [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/9\" class=\"abstract_t\">9</a>], migrate, and proliferate. Lipids accumulate early in fatty streak formation yielding both intracellular lipid and extracellular deposits, which produce the fatty streak. Biglycan, a small dermatan sulfate proteoglycan detected in the intima of atherosclerotic coronary artery segments, can bind and trap lipoproteins, including very low density lipoproteins and low density lipoprotein [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/10\" class=\"abstract_t\">10</a>]. The fatty streak can also contain T lymphocytes. (See <a href=\"#H27901126\" class=\"local\">'Inflammation'</a> below.) Foam cells constitute the hallmark of the early atheroma.</p><p>As these lesions expand, more smooth muscle cells accumulate in the intima. The smooth muscle cells within the deep layer of the fatty streak can undergo apoptosis, which associates with further macrophage accumulation and microvesicles that can calcify, perhaps contributing to the transition of fatty streaks into atherosclerotic plaques (<a href=\"image.htm?imageKey=CARD%2F56922\" class=\"graphic graphic_table graphicRef56922 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/11\" class=\"abstract_t\">11</a>].</p><p class=\"headingAnchor\" id=\"H2525668183\"><span class=\"h2\">Fibrous cap</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fibrous cap atheromas are defined as plaques with a well-defined lipid core covered by a fibrous cap, which may be relatively acellular (made of dense collagen) or may be rich in smooth cells. (See <a href=\"topic.htm?path=pathology-and-pathogenesis-of-the-vulnerable-plaque\" class=\"medical medical_review\">&quot;Pathology and pathogenesis of the vulnerable plaque&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H2525668191\"><span class=\"h2\">Vasa vasorum</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The vasa vasorum form a network of micro-vessels that originates primarily from the adventitial layer of large arteries. These vessels supply oxygen and nutrients to the outer layers of the arterial wall [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/12\" class=\"abstract_t\">12</a>]. As atherosclerotic plaques develop and expand, they acquire their own microvascular network, extending from the adventitia through the media and into the thickened intima [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/13\" class=\"abstract_t\">13</a>]. These thin-walled vessels are prone to disruption, leading to hemorrhage within the substance of the plaque and contributing to the progression of coronary atherosclerosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/14,15\" class=\"abstract_t\">14,15</a>]. </p><p class=\"headingAnchor\" id=\"H27901087\"><span class=\"h2\">Fibrous plaque</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The fibrous plaque evolves from the fatty streak via accumulation of connective tissue with an increased number of smooth muscle cells filled with lipids and often a deeper extracellular lipid pool.</p><p class=\"headingAnchor\" id=\"H27901094\"><span class=\"h2\">Advanced lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>More advanced lesions often contain a necrotic lipid-rich core, and eventually calcified regions (<a href=\"image.htm?imageKey=CARD%2F56922\" class=\"graphic graphic_table graphicRef56922 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Atheroma formation associates with coronary artery remodeling (<a href=\"image.htm?imageKey=CARD%2F68786\" class=\"graphic graphic_figure graphicRef68786 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/16\" class=\"abstract_t\">16</a>]. Positive remodeling involves expansion of the plaque and external elastic membrane area due to a compensatory increase in local vessel size, while negative remodeling refers to a smaller external elastic membrane area at the lesion site due to the local shrinkage of vessel size (<a href=\"image.htm?imageKey=CARD%2F72935%7ECARD%2F59588\" class=\"graphic graphic_diagnosticimage graphicRef72935 graphicRef59588 \">image 1A-B</a>). </p><p>Positive remodeling acts as a compensatory mechanism in early coronary artery disease, preventing luminal loss despite plaque accumulation. However, arterial remodeling consequent to plaque formation and expansion is associated with abnormal arterial physiology as well as the development of clinical symptoms [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/16\" class=\"abstract_t\">16</a>]. Positive remodeling is seen with complex, unstable plaques in patients presenting with unstable angina; in contrast, negative remodeling is associated with obstructive plaques in patients with stable angina [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/17\" class=\"abstract_t\">17</a>]. (See <a href=\"topic.htm?path=the-role-of-the-vulnerable-plaque-in-acute-coronary-syndromes\" class=\"medical medical_review\">&quot;The role of the vulnerable plaque in acute coronary syndromes&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H27901102\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple factors contribute to the pathogenesis of atherosclerosis, including endothelial dysfunction, dyslipidemia, inflammatory, and immunologic factors, plaque rupture, and smoking. (See <a href=\"topic.htm?path=overview-of-established-risk-factors-for-cardiovascular-disease\" class=\"medical medical_review\">&quot;Overview of established risk factors for cardiovascular disease&quot;</a> and <a href=\"topic.htm?path=cardiovascular-risk-of-smoking-and-benefits-of-smoking-cessation\" class=\"medical medical_review\">&quot;Cardiovascular risk of smoking and benefits of smoking cessation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H27901110\"><span class=\"h2\">Endothelial dysfunction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The endothelium forms an active biologic interface between the blood and all other tissues. The single layer of continuous endothelium lining arteries forms a unique thromboresistant layer between blood and potentially thrombogenic subendothelial tissues. The endothelium also modulates tone, growth, hemostasis, and inflammation throughout the circulatory system. Endothelial vasodilator dysfunction is an initial step in atherosclerosis and is felt to be caused principally by loss of endothelium-derived nitric oxide [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/18\" class=\"abstract_t\">18</a>]. This issue is discussed in detail separately and will only briefly be reviewed here. (See <a href=\"topic.htm?path=coronary-artery-endothelial-dysfunction-clinical-aspects\" class=\"medical medical_review\">&quot;Coronary artery endothelial dysfunction: Clinical aspects&quot;</a>.)</p><p>Endothelial dysfunction is associated with many of the traditional risk factors for atherosclerosis, including hypercholesterolemia, diabetes, hypertension, cigarette smoking. In particular, endothelial dysfunction is induced by oxidized low density lipoprotein (LDL) and in some respects can be considered as a final common pathway (<a href=\"image.htm?imageKey=CARD%2F56643\" class=\"graphic graphic_table graphicRef56643 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/19\" class=\"abstract_t\">19</a>]. It can be improved with correction of hyperlipidemia by diet or by therapy with a statin (HMG-coenzyme A reductase inhibitor), which increases the bioavailability of nitric oxide [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/20,21\" class=\"abstract_t\">20,21</a>], with angiotensin converting enzyme inhibitors [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/22\" class=\"abstract_t\">22</a>], or with high doses of antioxidants such as vitamin C or flavonoids contained in red wine and purple grape juice [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/23,24\" class=\"abstract_t\">23,24</a>]. However, clinical benefits of these therapies have only been demonstrated convincingly for statins. (See <a href=\"topic.htm?path=coronary-artery-endothelial-dysfunction-clinical-aspects\" class=\"medical medical_review\">&quot;Coronary artery endothelial dysfunction: Clinical aspects&quot;</a> and <a href=\"topic.htm?path=mechanisms-of-benefit-of-lipid-lowering-drugs-in-patients-with-coronary-heart-disease\" class=\"medical medical_review\">&quot;Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease&quot;</a> and <a href=\"topic.htm?path=nutritional-antioxidants-in-coronary-heart-disease\" class=\"medical medical_review\">&quot;Nutritional antioxidants in coronary heart disease&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H27901126\"><span class=\"h2\">Inflammation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Evidence of inflammation in atherosclerotic lesions has been noted from the earliest histologic observations and inflammation is central to understanding the pathogenesis of atherosclerosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/25-28\" class=\"abstract_t\">25-28</a>]. Macrophages that have taken up oxidized LDL release a variety of inflammatory substances, cytokines, and growth factors [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/29,30\" class=\"abstract_t\">29,30</a>]. Among the many molecules that have been implicated are: monocyte chemotactic protein (MCP)-1 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/31,32\" class=\"abstract_t\">31,32</a>]; intercellular adhesion molecule (ICAM)-1 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/31\" class=\"abstract_t\">31</a>]; macrophage and granulocyte-macrophage colony stimulating factors [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/33,34\" class=\"abstract_t\">33,34</a>]; CD40 ligand ; interleukin (IL)-1, IL-3, IL-6, IL-8, and IL-18 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/35-37\" class=\"abstract_t\">35-37</a>]; and tumor necrosis factor alpha [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/38-40\" class=\"abstract_t\">38-40</a>]. The role of IL-6 is discussed separately. (See <a href=\"topic.htm?path=overview-of-established-risk-factors-for-cardiovascular-disease#H835935\" class=\"medical medical_review\">&quot;Overview of established risk factors for cardiovascular disease&quot;, section on 'Interleukin-6'</a>.)</p><p>Evidence supporting the importance of inflammation in the pathogenesis of atherosclerosis comes from the observation that markers of increased or decreased systemic inflammation associated with the risk of atherosclerosis. Furthermore, the Cankinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) has demonstrated that inhibition of interleukin-1 beta with <a href=\"topic.htm?path=canakinumab-drug-information\" class=\"drug drug_general\">canakinumab</a> substantially lowered the inflammatory biomarkers hsCRP and IL-6 without changing atherogenic lipids in patients with a prior myocardial infarction. The risk of a composite of cardiovascular death, nonfatal myocardial infarction, and non-fatal stroke fell by 15 percent (p = 0.021) with canakinumab 150 mg subcutaneous injection every three months [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/41\" class=\"abstract_t\">41</a>]. Some of these markers are discussed in the next sections.</p><p class=\"headingAnchor\" id=\"H27901134\"><span class=\"h3\">Serum high sensitivity CRP (hsCRP)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>hsCRP is one of the downstream inflammatory markers. It consistently associates with the increased risk of atherosclerotic cardiovascular disease independent of cholesterol level [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/42,43\" class=\"abstract_t\">42,43</a>], although genetic data do not support its function as a causal risk factor. It has been considered as a useful marker to identify individuals with increased vascular inflammation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/41,44\" class=\"abstract_t\">41,44</a>]. The role of C-reactive protein in cardiovascular disease is discussed in detail separately. (See <a href=\"topic.htm?path=c-reactive-protein-in-cardiovascular-disease\" class=\"medical medical_review\">&quot;C-reactive protein in cardiovascular disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H41092680\"><span class=\"h3\">Lp-PLA2</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>) is a macrophage-secreted enzyme that may perpetuate plaque inflammation and whose elevated levels predict a 40 to 400 percent (averaging about 100 percent) increased risk of myocardial infarction (MI) and stroke in population studies fully adjusted for other cardiovascular disease risk factors. Clinical trials with an inhibitor of Lp-PLA<sub>2 </sub>[<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/45\" class=\"abstract_t\">45</a>] did not show improved outcomes. (See <a href=\"topic.htm?path=prevention-of-cardiovascular-disease-events-in-those-with-established-disease-or-at-high-risk#H45\" class=\"medical medical_review\">&quot;Prevention of cardiovascular disease events in those with established disease or at high risk&quot;, section on 'Therapies without well established benefit'</a>.)</p><p class=\"headingAnchor\" id=\"H27901149\"><span class=\"h3\">Cytokines</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cytokines may participate in the pathogenesis of atherosclerosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/46\" class=\"abstract_t\">46</a>]. Mediators such as interleukin-1 or tumor necrosis factor-alpha have a multitude of atherogenic effects. Basic science studies [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/47-49\" class=\"abstract_t\">47-49</a>] have identified that the proinflammatory cytokine interleukin-1&szlig; plays multiple roles in the development of atherosclerotic plaque and the favorable effects of inhibiting interleukin-1&szlig; signaling in animals with experimental atherosclerosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/50,51\" class=\"abstract_t\">50,51</a>].<strong> </strong>The cytokines enhance the expression of cell surface molecules such as ICAM-1, VCAM-1, CD40, and selectins on endothelial cells, smooth muscle cells, and macrophages. Pro-inflammatory cytokines can also induce cell proliferation, contribute to the production of reactive oxygen species, stimulate matrix metalloproteinases, and induce tissue factor expression. Other cytokines, such as interleukin-4 and interleukin-10, are antiatherogenic. Still others, such as interferon-gamma, can promote experimental atherogenesis. (See <a href=\"topic.htm?path=the-role-of-the-vulnerable-plaque-in-acute-coronary-syndromes\" class=\"medical medical_review\">&quot;The role of the vulnerable plaque in acute coronary syndromes&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H27901163\"><span class=\"h3\">Leukocyte activation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Leukocytes (circulating monocytes, and to a lesser extent T lymphocytes) accumulate early in the atherosclerotic lesion, providing evidence for the role of local inflammation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/52\" class=\"abstract_t\">52</a>].</p><p> Evidence in support of systemic inflammation comes from a study in which the inflammatory mRNA profile of circulating leukocytes was tested in 524 men with a prior MI and 628 controls [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/53\" class=\"abstract_t\">53</a>]. The patients, compared to controls, had mRNA profiles showing increased levels of many inflammatory mRNAs.</p><p class=\"headingAnchor\" id=\"H27901170\"><span class=\"h3\">Toll-like receptor 4</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Further evidence for the role of inflammation comes from study of polymorphisms in the toll-like receptor 4 gene that confer differences in the inflammatory response to Gram negative pathogens and perhaps other ligands [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/54\" class=\"abstract_t\">54</a>]. A particular polymorphism of this gene, Asp299Gly, presents in 7 percent of an Italian population, diminishes receptor cycling, and is associated with diminished inflammatory response to Gram-negative pathogens.</p><p>Carriers of the Asp299Gly polymorphism, compared to patients with only wild-type alleles, have reduced circulating levels of a variety of inflammatory markers, including CRP, adhesion molecules, and IL-6, and a reduced incidence of carotid atherosclerosis (odds ratio 0.54) as detected by ultrasonography. They have an increased rate of serious bacterial infections.</p><p class=\"headingAnchor\" id=\"H2536311117\"><span class=\"h3\">Pregnancy-associated plasma protein-A (PAPP-A)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PAPP-A is a high molecular weight, zinc-binding metalloproteinase that is thought to degrade the proteins that maintain the integrity of the protective fibrous cap of atherosclerotic plaques [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/55\" class=\"abstract_t\">55</a>]. PAPP-A can be produced by osteoblasts, fibroblasts, endothelial, vascular smooth muscle cells, and <span class=\"nowrap\">monocytes/macrophages</span> [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/56-60\" class=\"abstract_t\">56-60</a>], and has been identified in vulnerable coronary plaques but not in stable ones [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/61-63\" class=\"abstract_t\">61-63</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H41093640\"><span class=\"h2\">Dyslipidemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lipid abnormalities play a critical role in the development of atherosclerosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/30,64-70\" class=\"abstract_t\">30,64-70</a>]. Early experiments in animals demonstrated accelerated atherosclerosis with a high cholesterol diet. Subsequent epidemiologic studies conducted in countries around the world showed an increasing incidence of atherosclerosis when serum cholesterol concentrations were above 150 <span class=\"nowrap\">mg/dL</span> (3.9 <span class=\"nowrap\">mmol/L)</span> (<a href=\"image.htm?imageKey=CARD%2F60146\" class=\"graphic graphic_figure graphicRef60146 \">figure 3</a>).</p><p>The role of the different lipid particles in the development of atherosclerosis is discussed elsewhere. (See <a href=\"topic.htm?path=lipoprotein-classification-metabolism-and-role-in-atherosclerosis\" class=\"medical medical_review\">&quot;Lipoprotein classification, metabolism, and role in atherosclerosis&quot;</a>.)</p><p>It is useful, however, to summarize the major observations.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>High levels of LDL cholesterol [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/64,70\" class=\"abstract_t\">64,70</a>] are particularly important risk factors for atherosclerosis (<a href=\"image.htm?imageKey=CARD%2F70984\" class=\"graphic graphic_algorithm graphicRef70984 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/65\" class=\"abstract_t\">65</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cholesterol accumulates in the lipid-laden macrophages (foam cells), and in the lipid core, of atherosclerotic plaque [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/71\" class=\"abstract_t\">71</a>]. Oxidative modification of LDL facilitates macrophage uptake via unregulated macrophage scavenger receptors (among them, CD36, also called scavenger receptor B) and for accelerated accumulation of cholesterol [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/72,73\" class=\"abstract_t\">72,73</a>]. Macrophage uptake of LDL cholesterol may initially be an adaptive response, which prevents LDL-induced endothelial injury [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/74\" class=\"abstract_t\">74</a>]. However, cholesterol accumulation in foam cells leads to mitochondrial dysfunction, apoptosis, and necrosis, with resultant release of cellular proteases, inflammatory cytokines, and prothrombotic molecules [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/74\" class=\"abstract_t\">74</a>]. A large body of the accumulative evidence in the past 50 years has demonstrated that lowering LDL-C can reduce cardiovascular events and the lower levels of LDL-C achieved are associated with a better clinical outcome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/75,76\" class=\"abstract_t\">75,76</a>]. (See <a href=\"topic.htm?path=management-of-low-density-lipoprotein-cholesterol-ldl-c-in-secondary-prevention-of-cardiovascular-disease#H1672372062\" class=\"medical medical_review\">&quot;Management of low density lipoprotein cholesterol (LDL-C) in secondary prevention of cardiovascular disease&quot;, section on 'Benefits associated with LDL-C lowering'</a> and <a href=\"topic.htm?path=management-of-elevated-low-density-lipoprotein-cholesterol-ldl-c-in-primary-prevention-of-cardiovascular-disease#H2629267076\" class=\"medical medical_review\">&quot;Management of elevated low density lipoprotein-cholesterol (LDL-C) in primary prevention of cardiovascular disease&quot;, section on 'Rationale for LDL-C lowering in primary prevention'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HDL, in contrast to LDL, has putative antiatherogenic properties that include reverse cholesterol transport, maintenance of endothelial function, and protection against thrombosis. There is an inverse relationship between plasma HDL-cholesterol levels and cardiovascular risk (<a href=\"image.htm?imageKey=CARD%2F57480\" class=\"graphic graphic_table graphicRef57480 \">table 3</a>). Values above 75 <span class=\"nowrap\">mg/dL</span> (1.9 <span class=\"nowrap\">mmol/L)</span> are associated with a longevity syndrome. Values above 60 <span class=\"nowrap\">mg/dL</span> (1.5 <span class=\"nowrap\">mmol/L)</span> count as a negative risk factor in the Framingham Risk Assessment [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/77\" class=\"abstract_t\">77</a>]. However, cardiovascular disease event reduction from increasing HDL-cholesterol has not been established, particularly in patients with well-controlled LDL-cholesterol levels [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/78-80\" class=\"abstract_t\">78-80</a>]. A Mendelian randomization study showed that raised plasma HDL-cholesterol levels through some genetic mechanisms are not associated with lower risk of MI [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/81\" class=\"abstract_t\">81</a>]. Studies showed that HDL-cholesterol efflux had a close relationship with clinical atherosclerosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/82\" class=\"abstract_t\">82</a>] and CV events [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/83\" class=\"abstract_t\">83</a>]. These data challenge the concept that raising HDL-cholesterol levels will uniformly translate into a reduction in the risk of CV events. One explanation for the lack of benefit from therapies that raise HDL-cholesterol levels tested so far is that they may not improve the reverse cholesterol transport role of HDL. (See <a href=\"topic.htm?path=hdl-cholesterol-clinical-aspects-of-abnormal-values\" class=\"medical medical_review\">&quot;HDL cholesterol: Clinical aspects of abnormal values&quot;</a>.) Genetic studies have cast doubt on the causal relationship between low HDL levels and increased risk of atherosclerotic events. Thus, HDL may serve as a biomarker of risk, but no evidence yet shows that HDL-cholesterol is a modifiable risk factor. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Current epidemiologic and genetic evidence support a causal role for triglyceride-rich lipoproteins, particularly those that contain apolipoprotein C3.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An analysis in 60,608 individuals found that nonfasting remnant cholesterol, which is nonfasting total cholesterol minus HDL cholesterol and minus LDL cholesterol, associates causally with ischemic heart disease and with low-grade inflammation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/84,85\" class=\"abstract_t\">84,85</a>]. (See <a href=\"topic.htm?path=hypertriglyceridemia\" class=\"medical medical_review\">&quot;Hypertriglyceridemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oxidized lipoproteins including LDL [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/30\" class=\"abstract_t\">30</a>], HDL [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/86\" class=\"abstract_t\">86</a>], remnant lipoproteins [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/87\" class=\"abstract_t\">87</a>], and phospholipid [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/88\" class=\"abstract_t\">88</a>] have been thought to cause disruption of the endothelial cell surface, and promote inflammatory via cytokine release from macrophages, reduced cholesterol efflux, and the development of atherosclerosis. It may also play a role in plaque instability. Levels of oxidized LDL are increased in patients with an acute coronary syndrome and are positively correlated with the severity of the syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/89,90\" class=\"abstract_t\">89,90</a>]. In addition, antibodies to oxidized LDL have been found in human atherosclerotic plaques and in the plasma of patients with atherosclerosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/91,92\" class=\"abstract_t\">91,92</a>]. Measurement of oxidized lipoproteins remains for research to better understand the pathogenesis and has not been standardized or validated as a clinically useful biomarker. Furthermore, antioxidant strategies have consistently failed to improve cardiovascular outcomes in clinical trials.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Observational and genetic studies support a causal role for lipoprotein(a), which is LDL covalently linked to apolipoprotein (a). (See <a href=\"topic.htm?path=lipoprotein-a-and-cardiovascular-disease\" class=\"medical medical_review\">&quot;Lipoprotein(a) and cardiovascular disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The LDL moiety of Lp(a) promotes atherosclerosis, whereas the plasminogen-like apo(a) molecule may favor thrombus accumulation by interfering with fibrinolysis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/93,94\" class=\"abstract_t\">93,94</a>]. Additional functions of Lp(a) include initiation of signaling pathways in macrophages [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/95\" class=\"abstract_t\">95</a>] and vascular endothelial cells [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/96,97\" class=\"abstract_t\">96,97</a>], resulting in proatherogenic changes in cell phenotype and gene expression. Lp(a) binding to macrophages could lead to foam cell formation and localization of Lp(a) at atherosclerotic plaques [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/98\" class=\"abstract_t\">98</a>]. Lp(a) associates with increased residual cardiovascular event risk in JUPITER [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/97\" class=\"abstract_t\">97</a>] and AIM-HIGH [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/99\" class=\"abstract_t\">99</a>], which suggest that Lp(a) remains a risk factor in subjects with aggressive LDL-cholesterol lowering. (See <a href=\"topic.htm?path=lipoprotein-a-and-cardiovascular-disease\" class=\"medical medical_review\">&quot;Lipoprotein(a) and cardiovascular disease&quot;</a>.) &#160;</p><p/><p class=\"headingAnchor\" id=\"H41094192\"><span class=\"h2\">Hypertension</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypertension is a major risk factor for the development of atherosclerosis, particularly in the coronary and cerebral circulations [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/100-102\" class=\"abstract_t\">100-102</a>]. It can increase arterial wall tension, potentially leading to disturbed repair processes and aneurysm formation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H41094212\"><span class=\"h2\">Smoking</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cigarette smoking is another major risk factor [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/100-102\" class=\"abstract_t\">100-102</a>] and it impacts all phases of atherosclerosis from endothelial dysfunction to acute clinical events, the latter being largely thrombotic [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/103\" class=\"abstract_t\">103</a>]. The following observations have been made:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In humans, cigarette smoke exposure impairs endothelium-dependent vasodilation, perhaps through decreased nitric oxide (NO) availability [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/104-106\" class=\"abstract_t\">104-106</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cigarette smoking is associated with an increased level of multiple inflammatory markers, including C-reactive protein, interleukin-6, and tumor necrosis factor alpha in both male and female smokers [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/107-110\" class=\"abstract_t\">107-110</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cigarette smoking may decrease availability of platelet-derived NO, decrease platelet sensitivity to exogenous NO (both of which may lead to increased activation and adhesion) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/111,112\" class=\"abstract_t\">111,112</a>], increase fibrinogen levels [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/113,114\" class=\"abstract_t\">113,114</a>], and decrease fibrinolysis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/115\" class=\"abstract_t\">115</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cigarette smoking increases oxidative modification of LDL [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/116\" class=\"abstract_t\">116</a>] and decreases the plasma activity of paraoxonase, an enzyme that protects against LDL oxidation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/117\" class=\"abstract_t\">117</a>]. The <span class=\"nowrap\">triglyceride/HDL</span> abnormalities seen among smokers have been suggested to be related to insulin resistance [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/118\" class=\"abstract_t\">118</a>]. </p><p/><p class=\"headingAnchor\" id=\"H41094220\"><span class=\"h2\">Diabetes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to atherogenic effects from the diabetes-related dyslipidemia (elevated triglycerides, low level of HDL cholesterol, and <span class=\"nowrap\">small/dense</span> LDL particles), as mentioned above, many clinical and experimental studies reveal that high levels of insulin precede development of arterial diseases [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/119-125\" class=\"abstract_t\">119-125</a>]. Macrophages express most insulin signaling molecules except IR substrate 1 (IRS1) and glucose transporter type 4 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/126,127\" class=\"abstract_t\">126,127</a>]. Even though insulin activates the <span class=\"nowrap\">IR/IRS2/PI3K/Akt</span> pathway in macrophages as in other types of insulin-responsive cells, few studies have investigated the biological functions of insulin signaling in macrophages.</p><p>Atherosclerosis and type 2 diabetes share similar pathological mechanisms, including elevation in cytokines like MCP-1 and interleukin-6 (IL-6), which contribute to underlying inflammation of both [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/128,129\" class=\"abstract_t\">128,129</a>]. A published study [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/128\" class=\"abstract_t\">128</a>] evaluated if insulin affects macrophage foam cell formation and found that insulin increased the expression of CD36 and decreased ABCA-1 expression, which may promote cholesterol accumulation in human monocyte-derived macrophages. The study also showed that low concentration of adiponectin increased the phosphorylation of Akt (Ser436) by the same degree as insulin and had the same modulating effect on CD36 and ABCA-1 as insulin. Clinically, the overall risk increase conferred by type 2 diabetes is driven by accelerated progression of pre-existing atherosclerosis to clinical cardiovascular events [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/130\" class=\"abstract_t\">130</a>]. </p><p class=\"headingAnchor\" id=\"H27901191\"><span class=\"h2\">Tissue factor</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tissue factor is the primary initiator of coagulation and, in advanced atherosclerosis, is found in the plaque. (See <a href=\"topic.htm?path=overview-of-hemostasis\" class=\"medical medical_review\">&quot;Overview of hemostasis&quot;</a>.) Tissue factor, as well as other factors such as enhanced platelet activity, may contribute to the development of thrombosis following plaque disruption. (See <a href=\"topic.htm?path=the-role-of-the-vulnerable-plaque-in-acute-coronary-syndromes\" class=\"medical medical_review\">&quot;The role of the vulnerable plaque in acute coronary syndromes&quot;</a>.) Tissue factor also plays a role in the progression of atherosclerosis via coagulation-dependent and coagulation-independent mechanisms. In one study, tissue factor overexpression increased neointimal area and plaque size by increasing mural thrombus and smooth muscle cell migration and accelerating endothelial regrowth over the plaque after rupture [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/131\" class=\"abstract_t\">131</a>].</p><p class=\"headingAnchor\" id=\"H27901199\"><span class=\"h2\">Angiotensin II</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Increased plasma concentrations of angiotensin II promote the development and severity of atherosclerosis, particularly when combined with hyperlipidemia [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/132\" class=\"abstract_t\">132</a>].<strong> </strong>Angiotensin II may modulate vascular smooth muscle cell proliferation and the production of extracellular matrix [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/133,134\" class=\"abstract_t\">133,134</a>]. (See <a href=\"topic.htm?path=actions-of-angiotensin-ii-on-the-heart\" class=\"medical medical_review\">&quot;Actions of angiotensin II on the heart&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H27901207\"><span class=\"h2\">Endothelin-1</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endothelin-1 may contribute to the pathogenesis of atherosclerosis at all stages, even when the plaque is clinically imperceptible [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/135,136\" class=\"abstract_t\">135,136</a>]. Endothelin-1 is a potent vasoconstrictor as well as a mitogen for vascular smooth muscle cells, stimulating their migration and growth. Oxidized LDL can stimulate its production and enhance its vasoconstrictor effects [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/137\" class=\"abstract_t\">137</a>]. (See <a href=\"topic.htm?path=role-of-endothelin-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">&quot;Role of endothelin in heart failure with reduced ejection fraction&quot;</a>.)</p><p>Endothelin-1 immunoreactivity is ubiquitous within the intracellular and extracellular compartments of human coronary atherosclerotic tissue and is released from these sites in response to mechanical stress [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/138\" class=\"abstract_t\">138</a>]. In addition, endothelin-converting enzyme-1, the final enzyme for endothelin-1 production, is expressed in smooth muscle cells and macrophages of human coronary atherosclerotic lesions at all stages of development [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/136,139\" class=\"abstract_t\">136,139</a>].</p><p class=\"headingAnchor\" id=\"H27901215\"><span class=\"h2\">Adhesion molecules</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) are cell surface glycoproteins induced at endothelial sites of inflammation that mediate the adherence of leukocytes to endothelium. (See <a href=\"topic.htm?path=leukocyte-endothelial-adhesion-in-the-pathogenesis-of-inflammation\" class=\"medical medical_review\">&quot;Leukocyte-endothelial adhesion in the pathogenesis of inflammation&quot;</a>.) A low level of ICAM-1 is expressed on normal endothelial cells and is seen in normal arterial segments, while VCAM-1 expression occurs only with inflammation and is present in the microvessels of human atherosclerotic lesions [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/140\" class=\"abstract_t\">140</a>].</p><p>The expression of both ICAM-1 and VCAM-1 increases in atherosclerotic lesions, but VCAM-1 appears to be more important in the initiation of atherosclerosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/141\" class=\"abstract_t\">141</a>]. P-selectin, a platelet and endothelial cell receptor that mediates adhesion between vascular cells, also may promote migration of inflammatory cells into early and advanced atherosclerotic lesions [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/142,143\" class=\"abstract_t\">142,143</a>].</p><p>Monocyte adhesion to endothelial cells is reduced by L-arginine, the precursor of nitric oxide [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/144\" class=\"abstract_t\">144</a>] and alpha tocopherol (vitamin E), and increased by androgens due in part to enhanced endothelial cell-surface expression of VCAM-1 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/145\" class=\"abstract_t\">145</a>]. Antibodies that block adhesion molecules may ameliorate elements of the inflammatory response in atherosclerotic plaques [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/146\" class=\"abstract_t\">146</a>].</p><p class=\"headingAnchor\" id=\"H27901222\"><span class=\"h2\">Flow characteristics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The frequent occurrence of atheroma at sites of bends, branches, and bifurcations of coronary arteries suggests that<strong> </strong>altered blood flow and low shear stress can play a role in the development of atherosclerosis. Disturbed flow can alter endothelial cell function [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/147\" class=\"abstract_t\">147</a>] in a manner that impairs atheroprotective functions [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/29\" class=\"abstract_t\">29</a>]. These changes may be mediated by stimulation of the release of nitric oxide from the endothelial cells [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/148,149\" class=\"abstract_t\">148,149</a>].</p><p>Atherosclerosis preferentially affects regions of coronary arteries that experience low shear stress or disturbed flow [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/150\" class=\"abstract_t\">150</a>]. In addition, low shear stress is associated with an increase in intima medial thickness of the common carotid artery in healthy men [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/151\" class=\"abstract_t\">151</a>].</p><p class=\"headingAnchor\" id=\"H129408402\"><span class=\"h2\">Mitochondrial DNA damage</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The hypothesis that mitochondrial DNA (mtDNA) injury might lead to plaque development and vulnerability has been proposed and tested in experimental animal models [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/152,153\" class=\"abstract_t\">152,153</a>]. In the hyperlipidemic ApoE knockout mouse model, mtDNA lesions found in the aortas preceded the development of aortic plaques [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/154\" class=\"abstract_t\">154</a>]. More mtDNA lesions and larger plaque size were detected in the aortas of mice expressing mitochondrial mutation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/154\" class=\"abstract_t\">154</a>]. In patients, association of leukocyte mtDNA with atherosclerotic plaque vulnerability was examined in the Virtual Histology in Vulnerable Atherosclerosis (VIVA) trial [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/155\" class=\"abstract_t\">155</a>]. In this study, mtDNA lesions were found to be uniquely associated with thin-cap fibroatheroma, which are associated with a high risk of cardiovascular events [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/155,156\" class=\"abstract_t\">155,156</a>]. Taken together, these findings suggest a possible role of mtDNA injury in plaque progression and disruption. &#160;</p><p class=\"headingAnchor\" id=\"H1040053092\"><span class=\"h2\">Genetic associations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The genetic influences on atherosclerosis formation, progression, and atherosclerotic vascular events has attracted much attention. Two major genetic study approaches have been undertaken for a better understanding of the molecular mechanism of atherosclerosis. The first is the candidate gene approach, in which genes in known atherogenesis pathways are tested for their role in atherosclerosis in vitro, in vivo,<em> </em>and in association studies [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/157-159\" class=\"abstract_t\">157-159</a>]. The second approach is conducting genome-wide linkage studies to find atherogenesis-regulating quantitative trait loci. This method has the potential to find new atherosclerosis genes. The availability of whole genome sequences in humans and mice, especially the abundant single nucleotide polymorphism and haplotype information, has made it possible to perform genome-wide association studies, another unbiased approach, to identify disease genes relatively quickly as compared with traditional genetic methods [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/160\" class=\"abstract_t\">160</a>]. &#160;</p><p>The complex pathophysiological processes that occur in atherosclerosis probably do not arise from a single or small number of genes. In addition, environmental factors, and their interactions with genes, likely participate. In the general population, genetic polymorphisms occur in many genes in the pathways of lipid metabolism, inflammation, and thrombogenesis. </p><p>Genetic and genomic studies have helped to identify newer therapeutic targets in atherosclerosis. For example, discovery of genetic variants of PCSK9 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/161-167\" class=\"abstract_t\">161-167</a>] in regulating LDL-C levels has led to a rapid development of PCSK9 inhibitor as a potential therapy for LDL-C lowering and reducing cardiovascular events. Furthermore, genetic manipulations in animal models will accelerate the pace of atherosclerosis research [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/168\" class=\"abstract_t\">168</a>]. (See <a href=\"topic.htm?path=pcsk9-inhibitors-pharmacology-adverse-effects-and-use\" class=\"medical medical_review\">&quot;PCSK9 inhibitors: Pharmacology, adverse effects, and use&quot;</a>.) &#160; &#160; &#160;</p><p class=\"headingAnchor\" id=\"H27901244\"><span class=\"h2\">Infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic infection may contribute to the pathogenesis of atherosclerosis. The major organisms that have been reported are Chlamydia pneumoniae [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/169\" class=\"abstract_t\">169</a>], cytomegalovirus (CMV) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/170-180\" class=\"abstract_t\">170-180</a>], coxsackie B virus infection [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/181\" class=\"abstract_t\">181</a>], and Helicobacter pylori [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/182-184\" class=\"abstract_t\">182-184</a>]. (See <a href=\"topic.htm?path=overview-of-possible-risk-factors-for-cardiovascular-disease#H10122216\" class=\"medical medical_review\">&quot;Overview of possible risk factors for cardiovascular disease&quot;, section on 'Infection'</a>.) </p><p>In addition to individual infections, the total pathogen burden, ie, the number of pathogens to which an individual has been exposed, may be an important risk factor for atherosclerosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/185-188\" class=\"abstract_t\">185-188</a>]. Pathogen burden with atherosclerotic lesions has been directly assessed by testing for bacterial rDNA signatures by polymerase chain reaction in specimens obtained during catheter-based atherectomy [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/189\" class=\"abstract_t\">189</a>]. Bacterial DNA was found in all patients with a mean of 12 species per lesion; bacterial DNA was not seen in control material or any unaffected coronary arteries. It is possible that secondary colonization may accelerate disease progression. </p><p>Chronic infection could act by a number of mechanisms, including direct vascular injury and induction of a systemic inflammatory state. (See <a href=\"#H27901126\" class=\"local\">'Inflammation'</a> above.) </p><p>Despite the attractiveness of infection as a potential important contributing factor, clinical evidence to support its role is lacking, and antibiotic therapy does not reduce the risk of recurrent myocardial infarction. </p><p class=\"headingAnchor\" id=\"H27901297\"><span class=\"h3\">Effect of vaccination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Vaccination against influenza has been evaluated for a potential benefit in preventing cardiovascular disease [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/190-192\" class=\"abstract_t\">190-192</a>]. Several studies have found a beneficial effect of influenza vaccination on cardiovascular events [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/190,191\" class=\"abstract_t\">190,191</a>]. While these studies are of interest and do document a beneficial effect of influenza vaccination in older adults, they do not establish a causative relationship between influenza infection and the pathogenesis of atherosclerosis. (See <a href=\"topic.htm?path=seasonal-influenza-vaccination-in-adults#H14\" class=\"medical medical_review\">&quot;Seasonal influenza vaccination in adults&quot;, section on 'Older adults'</a> and <a href=\"topic.htm?path=geriatric-health-maintenance#H11\" class=\"medical medical_review\">&quot;Geriatric health maintenance&quot;, section on 'Influenza vaccine'</a>.)</p><p class=\"headingAnchor\" id=\"H41093121\"><span class=\"h1\">ROLE OF PLAQUE RUPTURE AND EROSION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Atherosclerosis is generally asymptomatic until the plaque stenosis exceeds 70 or 80 percent of the luminal diameter, which can produce a reduction in flow, as with coronary blood flow to myocardium. These stenotic lesions can produce typical symptoms of angina pectoris. Progression of atherosclerotic plaques involves two distinct processes: a chronic one that leads to luminal narrowing slowly, and an acute one that causes rapid luminal obstruction associated with plaque hemorrhage <span class=\"nowrap\">and/or</span> luminal thrombosis.</p><p>Acute coronary and cerebrovascular syndromes (unstable angina, myocardial infarction, sudden death, and stroke) are typically due to rupture or erosion of plaques leading to thrombosis, although these plaques may have less than 50 percent stenosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/193-195\" class=\"abstract_t\">193-195</a>]. In a review [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/196\" class=\"abstract_t\">196</a>] of 22 autopsy studies in which 1847 coronary arteries were examined, plaque rupture was the main cause of coronary thrombosis regardless of clinical presentation (myocardial infarction: 79 percent; sudden coronary death: 65 percent), age (&gt;60 years: 77 percent; &gt;60 years: 64 percent; unknown: 73 percent), sex (men: 76 percent; women: 55 percent), and continent (Europe: 72 percent; United States: 68 percent; Asia 81 percent).</p><p>Plaque erosion is identified when serial sectioning of the thrombosed arterial segment fails to reveal plaque rupture [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/197\" class=\"abstract_t\">197</a>]. Typically, the endothelium is missing at the erosion site, and the exposed intima consists predominantly of vascular smooth muscle cells and proteoglycans. Clinical studies of optical coherence tomography performed in patients presenting with acute myocardial infarction showed that the incidence of fibrous cap disruption was 73 percent, whereas plaque erosion was 23 percent and patients with plaque rupture had a higher incidence of thin cap fibroatheroma of 83 percent [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/198\" class=\"abstract_t\">198</a>]; results were very similar to autopsy studies. </p><p>Plaque rupture or erosion may also be silent; repeated silent ruptures and thrombosis, followed by wound healing, may cause progression of atherosclerosis, with an increase in plaque burden and percent stenosis and negative arterial remodeling [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/199\" class=\"abstract_t\">199</a>]. In studies of patients with acute coronary syndromes who underwent imaging with intravascular ultrasound (and were treated with percutaneous coronary intervention of the culprit lesion), recurrent major adverse cardiovascular events were predicted by the finding of culprit and non-culprit lesions with thin-cap fibroatheromas [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/155,156\" class=\"abstract_t\">155,156</a>]. </p><p>The pathology and pathogenesis of the vulnerable plaque and its role in acute coronary syndromes are discussed elsewhere. (See <a href=\"topic.htm?path=pathology-and-pathogenesis-of-the-vulnerable-plaque\" class=\"medical medical_review\">&quot;Pathology and pathogenesis of the vulnerable plaque&quot;</a> and <a href=\"topic.htm?path=the-role-of-the-vulnerable-plaque-in-acute-coronary-syndromes\" class=\"medical medical_review\">&quot;The role of the vulnerable plaque in acute coronary syndromes&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (See <a href=\"topic.htm?path=atherosclerosis-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Atherosclerosis (The Basics)&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H11408436\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple factors contribute to the pathogenesis of atherosclerosis and its complications, including endothelial dysfunction, inflammatory and immunologic factors, plaque rupture or erosion, and the traditional risk factors of hypertension, diabetes, dyslipidemia, and smoking. Despite the attractiveness of infection as a potential contributing factor, clinical evidence to support its role is lacking. (See <a href=\"#H27901102\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atherosclerosis begins in childhood with the development of fatty streaks. The advanced lesions of atherosclerosis occur with increasing frequency with aging. (See <a href=\"#H27901064\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The histologic stages of atherosclerosis include fatty streak, fibrous cap, fibrous plaques, and advances lesions. With the availability of advanced vascular imaging techniques, the plaque histological characteristics can be identified in vivo. (See <a href=\"#H41092387\" class=\"local\">'Histology'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/1\" class=\"nounderline abstract_t\">Faxon DP, Fuster V, Libby P, et al. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 2004; 109:2617.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/2\" class=\"nounderline abstract_t\">Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473:317.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/3\" class=\"nounderline abstract_t\">Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92:1355.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/4\" class=\"nounderline abstract_t\">Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001; 103:2705.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/5\" class=\"nounderline abstract_t\">McGill HC Jr, McMahan CA, Zieske AW, et al. Association of Coronary Heart Disease Risk Factors with microscopic qualities of coronary atherosclerosis in youth. Circulation 2000; 102:374.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/6\" class=\"nounderline abstract_t\">Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999; 281:727.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/7\" class=\"nounderline abstract_t\">van Dijk RA, Virmani R, von der Th&uuml;sen JH, et al. The natural history of aortic atherosclerosis: a systematic histopathological evaluation of the peri-renal region. Atherosclerosis 2010; 210:100.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/8\" class=\"nounderline abstract_t\">Davies MJ, Woolf N, Rowles PM, Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J 1988; 60:459.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/9\" class=\"nounderline abstract_t\">Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8:403.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/10\" class=\"nounderline abstract_t\">O'Brien KD, Olin KL, Alpers CE, et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 1998; 98:519.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/11\" class=\"nounderline abstract_t\">Kockx MM, De Meyer GR, Muhring J, et al. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 1998; 97:2307.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/12\" class=\"nounderline abstract_t\">Heistad DD, Marcus ML, Larsen GE, Armstrong ML. Role of vasa vasorum in nourishment of the aortic wall. Am J Physiol 1981; 240:H781.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/13\" class=\"nounderline abstract_t\">Barger AC, Beeuwkes R 3rd, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984; 310:175.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/14\" class=\"nounderline abstract_t\">Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349:2316.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/15\" class=\"nounderline abstract_t\">Virmani R, Narula J, Farb A. When neoangiogenesis ricochets. Am Heart J 1998; 136:937.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/16\" class=\"nounderline abstract_t\">Schoenhagen P, Ziada KM, Vince DG, et al. Arterial remodeling and coronary artery disease: the concept of &quot;dilated&quot; versus &quot;obstructive&quot; coronary atherosclerosis. J Am Coll Cardiol 2001; 38:297.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/17\" class=\"nounderline abstract_t\">Schoenhagen P, Ziada KM, Kapadia SR, et al. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes : an intravascular ultrasound study. Circulation 2000; 101:598.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/18\" class=\"nounderline abstract_t\">Kitta Y, Obata JE, Nakamura T, et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol 2009; 53:323.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/19\" class=\"nounderline abstract_t\">Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996; 93:1647.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/20\" class=\"nounderline abstract_t\">Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987; 80:1808.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/21\" class=\"nounderline abstract_t\">John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998; 98:211.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/22\" class=\"nounderline abstract_t\">Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94:258.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/23\" class=\"nounderline abstract_t\">Levine GN, Frei B, Koulouris SN, et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 93:1107.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/24\" class=\"nounderline abstract_t\">Stein JH, Keevil JG, Wiebe DA, et al. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation 1999; 100:1050.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/25\" class=\"nounderline abstract_t\">Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation 2004; 109:III20.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/26\" class=\"nounderline abstract_t\">Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/27\" class=\"nounderline abstract_t\">Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54:2129.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/28\" class=\"nounderline abstract_t\">Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17:1410.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/29\" class=\"nounderline abstract_t\">Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91:2488.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/30\" class=\"nounderline abstract_t\">Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30:2311.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/31\" class=\"nounderline abstract_t\">Gawaz M, Neumann FJ, Dickfeld T, et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998; 98:1164.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/32\" class=\"nounderline abstract_t\">Tsao PS, Wang B, Buitrago R, et al. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997; 96:934.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/33\" class=\"nounderline abstract_t\">Takahashi M, Kitagawa S, Masuyama JI, et al. Human monocyte-endothelial cell interaction induces synthesis of granulocyte-macrophage colony-stimulating factor. Circulation 1996; 93:1185.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/34\" class=\"nounderline abstract_t\">Rajavashisth T, Qiao JH, Tripathi S, et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice. J Clin Invest 1998; 101:2702.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/35\" class=\"nounderline abstract_t\">Rectenwald JE, Moldawer LL, Huber TS, et al. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 2000; 102:1697.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/36\" class=\"nounderline abstract_t\">Brizzi MF, Formato L, Dentelli P, et al. Interleukin-3 stimulates migration and proliferation of vascular smooth muscle cells: a potential role in atherogenesis. Circulation 2001; 103:549.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/37\" class=\"nounderline abstract_t\">Simonini A, Moscucci M, Muller DW, et al. IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation 2000; 101:1519.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/38\" class=\"nounderline abstract_t\">Li H, Freeman MW, Libby P. Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. J Clin Invest 1995; 95:122.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/39\" class=\"nounderline abstract_t\">Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000; 102:2636.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/40\" class=\"nounderline abstract_t\">Kaartinen M, Penttil&auml; A, Kovanen PT. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-alpha. Circulation 1996; 94:2787.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/41\" class=\"nounderline abstract_t\">Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377:1119.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/42\" class=\"nounderline abstract_t\">Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/43\" class=\"nounderline abstract_t\">Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/44\" class=\"nounderline abstract_t\">Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/45\" class=\"nounderline abstract_t\">Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008; 101:51F.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/46\" class=\"nounderline abstract_t\">Young JL, Libby P, Sch&ouml;nbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002; 88:554.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/47\" class=\"nounderline abstract_t\">Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:656.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/48\" class=\"nounderline abstract_t\">Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest 1996; 97:769.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/49\" class=\"nounderline abstract_t\">Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464:1357.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/50\" class=\"nounderline abstract_t\">Elhage R, Maret A, Pieraggi MT, et al. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 1998; 97:242.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/51\" class=\"nounderline abstract_t\">Isoda K, Sawada S, Ishigami N, et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24:1068.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/52\" class=\"nounderline abstract_t\">Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 2006; 47:C7.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/53\" class=\"nounderline abstract_t\">Wettinger SB, Doggen CJ, Spek CA, et al. High throughput mRNA profiling highlights associations between myocardial infarction and aberrant expression of inflammatory molecules in blood cells. Blood 2005; 105:2000.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/54\" class=\"nounderline abstract_t\">Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347:185.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/55\" class=\"nounderline abstract_t\">Laursen LS, Overgaard MT, Nielsen CG, et al. Substrate specificity of the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) assessed by mutagenesis and analysis of synthetic peptides: substrate residues distant from the scissile bond are critical for proteolysis. Biochem J 2002; 367:31.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/56\" class=\"nounderline abstract_t\">Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A 1999; 96:3149.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/57\" class=\"nounderline abstract_t\">Ortiz CO, Chen BK, Bale LK, et al. Transforming growth factor-beta regulation of the insulin-like growth factor binding protein-4 protease system in cultured human osteoblasts. J Bone Miner Res 2003; 18:1066.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/58\" class=\"nounderline abstract_t\">Conover CA, Harrington SC, Bale LK. Differential regulation of pregnancy associated plasma protein-A in human coronary artery endothelial cells and smooth muscle cells. Growth Horm IGF Res 2008; 18:213.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/59\" class=\"nounderline abstract_t\">Li W, Li H, Gu F. CRP and TNF-&alpha;&thinsp;&thinsp;induce PAPP-A expression in human peripheral blood mononuclear cells. Mediators Inflamm 2012; 2012:697832.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/60\" class=\"nounderline abstract_t\">Sangiorgi G, Mauriello A, Bonanno E, et al. Pregnancy-associated plasma protein-a is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events. J Am Coll Cardiol 2006; 47:2201.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/61\" class=\"nounderline abstract_t\">Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345:1022.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/62\" class=\"nounderline abstract_t\">Iversen KK, Dalsgaard M, Teisner AS, et al. Pregnancy-associated plasma protein-A, a marker for outcome in patients suspected for acute coronary syndrome. Clin Biochem 2010; 43:851.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/63\" class=\"nounderline abstract_t\">Iversen KK, Dalsgaard M, Teisner AS, et al. Usefulness of pregnancy-associated plasma protein A in patients with acute coronary syndrome. Am J Cardiol 2009; 104:1465.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/64\" class=\"nounderline abstract_t\">Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 1988; 148:36.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/65\" class=\"nounderline abstract_t\">Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62:707.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/66\" class=\"nounderline abstract_t\">Romm PA, Green CE, Reagan K, Rackley CE. Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease. Am J Cardiol 1991; 67:479.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/67\" class=\"nounderline abstract_t\">Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85:37.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/68\" class=\"nounderline abstract_t\">Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993; 328:1220.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/69\" class=\"nounderline abstract_t\">Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular M&uuml;nster study. Am J Cardiol 1992; 70:733.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/70\" class=\"nounderline abstract_t\">Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/71\" class=\"nounderline abstract_t\">Iuliano L, Mauriello A, Sbarigia E, et al. Radiolabeled native low-density lipoprotein injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque : effect of vitamin E supplementation. Circulation 2000; 101:1249.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/72\" class=\"nounderline abstract_t\">Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 2000; 105:1095.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/73\" class=\"nounderline abstract_t\">Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108:785.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/74\" class=\"nounderline abstract_t\">Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 2002; 110:905.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/75\" class=\"nounderline abstract_t\">Silverman MG, Ference BA, Im K, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA 2016; 316:1289.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/76\" class=\"nounderline abstract_t\">Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376:1713.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/77\" class=\"nounderline abstract_t\">National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/78\" class=\"nounderline abstract_t\">AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/79\" class=\"nounderline abstract_t\">Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367:2089.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/80\" class=\"nounderline abstract_t\">HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34:1279.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/81\" class=\"nounderline abstract_t\">Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380:572.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/82\" class=\"nounderline abstract_t\">Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/83\" class=\"nounderline abstract_t\">Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014; 371:2383.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/84\" class=\"nounderline abstract_t\">Varbo A, Benn M, Tybj&aelig;rg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61:427.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/85\" class=\"nounderline abstract_t\">Varbo A, Benn M, Tybj&aelig;rg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013; 128:1298.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/86\" class=\"nounderline abstract_t\">Khine HW, Teiber JF, Haley RW, et al. Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: Observations from the Dallas Heart Study. Atherosclerosis 2017; 263:156.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/87\" class=\"nounderline abstract_t\">Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta 2006; 367:36.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/88\" class=\"nounderline abstract_t\">Berliner JA, Leitinger N, Tsimikas S. The role of oxidized phospholipids in atherosclerosis. J Lipid Res 2009; 50 Suppl:S207.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/89\" class=\"nounderline abstract_t\">Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103:1955.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/90\" class=\"nounderline abstract_t\">Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003; 41:360.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/91\" class=\"nounderline abstract_t\">Inoue T, Uchida T, Kamishirado H, et al. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol 2001; 37:775.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/92\" class=\"nounderline abstract_t\">Bui MN, Sack MN, Moutsatsos G, et al. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J 1996; 131:663.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/93\" class=\"nounderline abstract_t\">Boffa MB, Koschinsky ML. Update on lipoprotein(a) as a cardiovascular risk factor and mediator. Curr Atheroscler Rep 2013; 15:360.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/94\" class=\"nounderline abstract_t\">Angl&eacute;s-Cano E, de la Pe&ntilde;a D&iacute;az A, Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 2001; 936:261.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/95\" class=\"nounderline abstract_t\">Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 2010; 12:467.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/96\" class=\"nounderline abstract_t\">Cho T, Jung Y, Koschinsky ML. Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem 2008; 283:30503.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/97\" class=\"nounderline abstract_t\">Cho T, Romagnuolo R, Scipione C, et al. Apolipoprotein(a) stimulates nuclear translocation of &beta;-catenin: a novel pathogenic mechanism for lipoprotein(a). Mol Biol Cell 2013; 24:210.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/98\" class=\"nounderline abstract_t\">Zioncheck TF, Powell LM, Rice GC, et al. Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest 1991; 87:767.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/99\" class=\"nounderline abstract_t\">Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013; 62:1575.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/100\" class=\"nounderline abstract_t\">DAWBER TR, MEADORS GF, MOORE FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health 1951; 41:279.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/101\" class=\"nounderline abstract_t\">Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/102\" class=\"nounderline abstract_t\">Frohlich J, Al-Sarraf A. Cardiovascular risk and atherosclerosis prevention. Cardiovasc Pathol 2013; 22:16.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/103\" class=\"nounderline abstract_t\">Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43:1731.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/104\" class=\"nounderline abstract_t\">Mayhan WG, Sharpe GM. Effect of cigarette smoke extract on arteriolar dilatation in vivo. J Appl Physiol (1985) 1996; 81:1996.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/105\" class=\"nounderline abstract_t\">Mayhan WG, Patel KP. Effect of nicotine on endothelium-dependent arteriolar dilatation in vivo. Am J Physiol 1997; 272:H2337.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/106\" class=\"nounderline abstract_t\">Ota Y, Kugiyama K, Sugiyama S, et al. Impairment of endothelium-dependent relaxation of rabbit aortas by cigarette smoke extract--role of free radicals and attenuation by captopril. Atherosclerosis 1997; 131:195.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/107\" class=\"nounderline abstract_t\">Tracy RP, Psaty BM, Macy E, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997; 17:2167.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/108\" class=\"nounderline abstract_t\">Bermudez EA, Rifai N, Buring JE, et al. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol 2002; 89:1117.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/109\" class=\"nounderline abstract_t\">Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997; 78:273.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/110\" class=\"nounderline abstract_t\">Tappia PS, Troughton KL, Langley-Evans SC, Grimble RF. Cigarette smoking influences cytokine production and antioxidant defences. Clin Sci (Lond) 1995; 88:485.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/111\" class=\"nounderline abstract_t\">Ichiki K, Ikeda H, Haramaki N, et al. Long-term smoking impairs platelet-derived nitric oxide release. Circulation 1996; 94:3109.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/112\" class=\"nounderline abstract_t\">Sawada M, Kishi Y, Numano F, Isobe M. Smokers lack morning increase in platelet sensitivity to nitric oxide. J Cardiovasc Pharmacol 2002; 40:571.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/113\" class=\"nounderline abstract_t\">Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113:1006.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/114\" class=\"nounderline abstract_t\">Smith FB, Lee AJ, Fowkes FG, et al. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17:3321.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/115\" class=\"nounderline abstract_t\">Barua RS, Ambrose JA, Saha DC, Eales-Reynolds LJ. Smoking is associated with altered endothelial-derived fibrinolytic and antithrombotic factors: an in vitro demonstration. Circulation 2002; 106:905.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/116\" class=\"nounderline abstract_t\">Heitzer T, Yl&auml;-Herttuala S, Luoma J, et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation 1996; 93:1346.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/117\" class=\"nounderline abstract_t\">Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 1997; 236:289.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/118\" class=\"nounderline abstract_t\">Reaven G, Tsao PS. Insulin resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardiovascular disease? J Am Coll Cardiol 2003; 41:1044.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/119\" class=\"nounderline abstract_t\">Py&ouml;r&auml;la K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2:131.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/120\" class=\"nounderline abstract_t\">Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2:154.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/121\" class=\"nounderline abstract_t\">Ducimetiere P, Eschwege E, Papoz L, et al. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980; 19:205.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/122\" class=\"nounderline abstract_t\">Py&ouml;r&auml;l&auml; K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl 1985; 701:38.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/123\" class=\"nounderline abstract_t\">Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res Suppl 1985; 15:41.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/124\" class=\"nounderline abstract_t\">Haffner SM, Stern MP, Hazuda HP, et al. Hyperinsulinemia in a population at high risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1986; 315:220.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/125\" class=\"nounderline abstract_t\">R&ouml;nnemaa T, Laakso M, Py&ouml;r&auml;l&auml; K, et al. High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. Arterioscler Thromb 1991; 11:80.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/126\" class=\"nounderline abstract_t\">Welham MJ, Bone H, Levings M, et al. Insulin receptor substrate-2 is the major 170-kDa protein phosphorylated on tyrosine in response to cytokines in murine lymphohemopoietic cells. J Biol Chem 1997; 272:1377.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/127\" class=\"nounderline abstract_t\">Malide D, Davies-Hill TM, Levine M, Simpson IA. Distinct localization of GLUT-1, -3, and -5 in human monocyte-derived macrophages: effects of cell activation. Am J Physiol 1998; 274:E516.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/128\" class=\"nounderline abstract_t\">Park YM, R Kashyap S, A Major J, Silverstein RL. Insulin promotes macrophage foam cell formation: potential implications in diabetes-related atherosclerosis. Lab Invest 2012; 92:1171.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/129\" class=\"nounderline abstract_t\">Fern&aacute;ndez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24:278.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/130\" class=\"nounderline abstract_t\">Saely CH, Rein P, Vonbank A, et al. Type 2 diabetes and the progression of visualized atherosclerosis to clinical cardiovascular events. Int J Cardiol 2013; 167:776.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/131\" class=\"nounderline abstract_t\">Hasenstab D, Lea H, Hart CE, et al. Tissue factor overexpression in rat arterial neointima models thrombosis and progression of advanced atherosclerosis. Circulation 2000; 101:2651.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/132\" class=\"nounderline abstract_t\">Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105:1605.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/133\" class=\"nounderline abstract_t\">Potter DD, Sobey CG, Tompkins PK, et al. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998; 98:800.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/134\" class=\"nounderline abstract_t\">Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101:1586.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/135\" class=\"nounderline abstract_t\">Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325:997.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/136\" class=\"nounderline abstract_t\">Ihling C, Szombathy T, Bohrmann B, et al. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 2001; 104:864.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/137\" class=\"nounderline abstract_t\">Mathew V, Cannan CR, Miller VM, et al. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation 1997; 96:1930.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/138\" class=\"nounderline abstract_t\">Hasdai D, Holmes DR Jr, Garratt KN, et al. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation 1997; 95:357.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/139\" class=\"nounderline abstract_t\">Minamino T, Kurihara H, Takahashi M, et al. Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis. Circulation 1997; 95:221.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/140\" class=\"nounderline abstract_t\">Iiyama K, Hajra L, Iiyama M, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 1999; 85:199.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/141\" class=\"nounderline abstract_t\">Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107:1255.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/142\" class=\"nounderline abstract_t\">Johnson RC, Chapman SM, Dong ZM, et al. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest 1997; 99:1037.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/143\" class=\"nounderline abstract_t\">Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 2000; 101:2290.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/144\" class=\"nounderline abstract_t\">Adams MR, Jessup W, Hailstones D, Celermajer DS. L-arginine reduces human monocyte adhesion to vascular endothelium and endothelial expression of cell adhesion molecules. Circulation 1997; 95:662.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/145\" class=\"nounderline abstract_t\">McCrohon JA, Jessup W, Handelsman DJ, Celermajer DS. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation 1999; 99:2317.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/146\" class=\"nounderline abstract_t\">Patel SS, Thiagarajan R, Willerson JT, Yeh ET. Inhibition of alpha4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice. Circulation 1998; 97:75.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/147\" class=\"nounderline abstract_t\">Hagiwara H, Mitsumata M, Yamane T, et al. Laminar shear stress-induced GRO mRNA and protein expression in endothelial cells. Circulation 1998; 98:2584.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/148\" class=\"nounderline abstract_t\">Tsao PS, Buitrago R, Chan JR, Cooke JP. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. Circulation 1996; 94:1682.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/149\" class=\"nounderline abstract_t\">Gimbrone MA Jr, Garc&iacute;a-Carde&ntilde;a G. Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc Pathol 2013; 22:9.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/150\" class=\"nounderline abstract_t\">Nwasokwa ON, Weiss M, Gladstone C, Bodenheimer MM. Effect of coronary artery size on the prevalence of atherosclerosis. Am J Cardiol 1996; 78:741.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/151\" class=\"nounderline abstract_t\">Gnasso A, Carallo C, Irace C, et al. Association between intima-media thickness and wall shear stress in common carotid arteries in healthy male subjects. Circulation 1996; 94:3257.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/152\" class=\"nounderline abstract_t\">Yu E, Mercer J, Bennett M. Mitochondria in vascular disease. Cardiovasc Res 2012; 95:173.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/153\" class=\"nounderline abstract_t\">Davidson SM, Yellon DM. Mitochondrial DNA damage, oxidative stress, and atherosclerosis: where there is smoke there is not always fire. Circulation 2013; 128:681.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/154\" class=\"nounderline abstract_t\">Yu E, Calvert PA, Mercer JR, et al. Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans. Circulation 2013; 128:702.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/155\" class=\"nounderline abstract_t\">Calvert PA, Obaid DR, O'Sullivan M, et al. Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc Imaging 2011; 4:894.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/156\" class=\"nounderline abstract_t\">Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011; 364:226.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/157\" class=\"nounderline abstract_t\">Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet 2004; 5:189.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/158\" class=\"nounderline abstract_t\">Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6:508.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/159\" class=\"nounderline abstract_t\">Arnett DK, Baird AE, Barkley RA, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007; 115:2878.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/160\" class=\"nounderline abstract_t\">Chen Y, Rollins J, Paigen B, Wang X. Genetic and genomic insights into the molecular basis of atherosclerosis. Cell Metab 2007; 6:164.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/161\" class=\"nounderline abstract_t\">Cameron J, Holla &Oslash;L, Ranheim T, et al. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 2006; 15:1551.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/162\" class=\"nounderline abstract_t\">Abifadel M, Rab&egrave;s JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009; 30:520.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/163\" class=\"nounderline abstract_t\">Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50 Suppl:S172.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/164\" class=\"nounderline abstract_t\">Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37:161.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/165\" class=\"nounderline abstract_t\">Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79:514.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/166\" class=\"nounderline abstract_t\">Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/167\" class=\"nounderline abstract_t\">Benn M, Nordestgaard BG, Grande P, et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010; 55:2833.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/168\" class=\"nounderline abstract_t\">Daugherty A, Tabas I, Rader DJ. Accelerating the pace of atherosclerosis research. Arterioscler Thromb Vasc Biol 2015; 35:11.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/169\" class=\"nounderline abstract_t\">Joshi R, Khandelwal B, Joshi D, Gupta OP. Chlamydophila pneumoniae infection and cardiovascular disease. N Am J Med Sci 2013; 5:169.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/170\" class=\"nounderline abstract_t\">Adler SP, Hur JK, Wang JB, Vetrovec GW. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998; 177:209.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/171\" class=\"nounderline abstract_t\">Blum A, Giladi M, Weinberg M, et al. High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol 1998; 81:866.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/172\" class=\"nounderline abstract_t\">Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998; 98:2796.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/173\" class=\"nounderline abstract_t\">Sorlie PD, Nieto FJ, Adam E, et al. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arch Intern Med 2000; 160:2027.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/174\" class=\"nounderline abstract_t\">Zhu J, Nieto FJ, Horne BD, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001; 103:45.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/175\" class=\"nounderline abstract_t\">Rupprecht HJ, Blankenberg S, Bickel C, et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 2001; 104:25.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/176\" class=\"nounderline abstract_t\">Adam E, Melnick JL, Probtsfield JL, et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987; 2:291.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/177\" class=\"nounderline abstract_t\">Nieto FJ, Adam E, Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996; 94:922.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/178\" class=\"nounderline abstract_t\">Melnick JL, Hu C, Burek J, et al. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol 1994; 42:170.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/179\" class=\"nounderline abstract_t\">Zhou YF, Guetta E, Yu ZX, et al. Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells. J Clin Invest 1996; 98:2129.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/180\" class=\"nounderline abstract_t\">Zhou YF, Shou M, Guetta E, et al. Cytomegalovirus infection of rats increases the neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall. Circulation 1999; 100:1569.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/181\" class=\"nounderline abstract_t\">Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 1999; 100:e20.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/182\" class=\"nounderline abstract_t\">Patel P, Mendall MA, Carrington D, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311:711.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/183\" class=\"nounderline abstract_t\">Gunn M, Stephens JC, Thompson JR, et al. Significant association of cagA positive Helicobacter pylori strains with risk of premature myocardial infarction. Heart 2000; 84:267.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/184\" class=\"nounderline abstract_t\">Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ 1998; 316:1130.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/185\" class=\"nounderline abstract_t\">Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002; 105:15.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/186\" class=\"nounderline abstract_t\">Prasad A, Zhu J, Halcox JP, et al. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation 2002; 106:184.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/187\" class=\"nounderline abstract_t\">Anderson JL, Carlquist JF, Muhlestein JB, et al. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998; 32:35.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/188\" class=\"nounderline abstract_t\">Mayr M, Kiechl S, Willeit J, et al. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000; 102:833.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/189\" class=\"nounderline abstract_t\">Ott SJ, El Mokhtari NE, Musfeldt M, et al. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 2006; 113:929.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/190\" class=\"nounderline abstract_t\">Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002; 105:2143.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/191\" class=\"nounderline abstract_t\">Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348:1322.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/192\" class=\"nounderline abstract_t\">Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000; 102:3039.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/193\" class=\"nounderline abstract_t\">Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/194\" class=\"nounderline abstract_t\">Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78:1157.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/195\" class=\"nounderline abstract_t\">Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12:56.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/196\" class=\"nounderline abstract_t\">Falk E, Nakano M, Bentzon JF, et al. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2013; 34:719.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/197\" class=\"nounderline abstract_t\">Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/198\" class=\"nounderline abstract_t\">Kubo T, Imanishi T, Takarada S, et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol 2007; 50:933.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-atherosclerosis/abstract/199\" class=\"nounderline abstract_t\">Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103:934.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13603 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H11408436\"><span>SUMMARY</span></a></li><li><a href=\"#H27901057\" id=\"outline-link-H27901057\">INTRODUCTION</a></li><li><a href=\"#H27901064\" id=\"outline-link-H27901064\">EPIDEMIOLOGY</a></li><li><a href=\"#H41092387\" id=\"outline-link-H41092387\">HISTOLOGY</a><ul><li><a href=\"#H27901080\" id=\"outline-link-H27901080\">Fatty streaks</a></li><li><a href=\"#H2525668183\" id=\"outline-link-H2525668183\">Fibrous cap</a></li><li><a href=\"#H2525668191\" id=\"outline-link-H2525668191\">Vasa vasorum</a></li><li><a href=\"#H27901087\" id=\"outline-link-H27901087\">Fibrous plaque</a></li><li><a href=\"#H27901094\" id=\"outline-link-H27901094\">Advanced lesions</a></li></ul></li><li><a href=\"#H27901102\" id=\"outline-link-H27901102\">PATHOGENESIS</a><ul><li><a href=\"#H27901110\" id=\"outline-link-H27901110\">Endothelial dysfunction</a></li><li><a href=\"#H27901126\" id=\"outline-link-H27901126\">Inflammation</a><ul><li><a href=\"#H27901134\" id=\"outline-link-H27901134\">- Serum high sensitivity CRP (hsCRP)</a></li><li><a href=\"#H41092680\" id=\"outline-link-H41092680\">- Lp-PLA2</a></li><li><a href=\"#H27901149\" id=\"outline-link-H27901149\">- Cytokines</a></li><li><a href=\"#H27901163\" id=\"outline-link-H27901163\">- Leukocyte activation</a></li><li><a href=\"#H27901170\" id=\"outline-link-H27901170\">- Toll-like receptor 4</a></li><li><a href=\"#H2536311117\" id=\"outline-link-H2536311117\">- Pregnancy-associated plasma protein-A (PAPP-A)</a></li></ul></li><li><a href=\"#H41093640\" id=\"outline-link-H41093640\">Dyslipidemia</a></li><li><a href=\"#H41094192\" id=\"outline-link-H41094192\">Hypertension</a></li><li><a href=\"#H41094212\" id=\"outline-link-H41094212\">Smoking</a></li><li><a href=\"#H41094220\" id=\"outline-link-H41094220\">Diabetes</a></li><li><a href=\"#H27901191\" id=\"outline-link-H27901191\">Tissue factor</a></li><li><a href=\"#H27901199\" id=\"outline-link-H27901199\">Angiotensin II</a></li><li><a href=\"#H27901207\" id=\"outline-link-H27901207\">Endothelin-1</a></li><li><a href=\"#H27901215\" id=\"outline-link-H27901215\">Adhesion molecules</a></li><li><a href=\"#H27901222\" id=\"outline-link-H27901222\">Flow characteristics</a></li><li><a href=\"#H129408402\" id=\"outline-link-H129408402\">Mitochondrial DNA damage</a></li><li><a href=\"#H1040053092\" id=\"outline-link-H1040053092\">Genetic associations</a></li><li><a href=\"#H27901244\" id=\"outline-link-H27901244\">Infection</a><ul><li><a href=\"#H27901297\" id=\"outline-link-H27901297\">- Effect of vaccination</a></li></ul></li></ul></li><li><a href=\"#H41093121\" id=\"outline-link-H41093121\">ROLE OF PLAQUE RUPTURE AND EROSION</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H23669508\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H11408436\" id=\"outline-link-H11408436\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/13603|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=CARD/70984\" class=\"graphic graphic_algorithm\">- Role of LDL in atherosclerosis</a></li></ul></li><li><div id=\"CARD/13603|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/72935\" class=\"graphic graphic_diagnosticimage\">- Negative remodeling IVUS</a></li><li><a href=\"image.htm?imageKey=CARD/59588\" class=\"graphic graphic_diagnosticimage\">- Positive remodeling IVUS</a></li></ul></li><li><div id=\"CARD/13603|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/76466\" class=\"graphic graphic_figure\">- Early coronary atherosclerosis</a></li><li><a href=\"image.htm?imageKey=CARD/68786\" class=\"graphic graphic_figure\">- Positive and negative remodel</a></li><li><a href=\"image.htm?imageKey=CARD/60146\" class=\"graphic graphic_figure\">- Association of increasing plasma cholesterol and coronary risk</a></li></ul></li><li><div id=\"CARD/13603|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/56922\" class=\"graphic graphic_table\">- AHA lesion classification</a></li><li><a href=\"image.htm?imageKey=CARD/56643\" class=\"graphic graphic_table\">- Endothelial dysfunction factors</a></li><li><a href=\"image.htm?imageKey=CARD/57480\" class=\"graphic graphic_table\">- HDL-C and cardiovascular risk</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=actions-of-angiotensin-ii-on-the-heart\" class=\"medical medical_review\">Actions of angiotensin II on the heart</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=c-reactive-protein-in-cardiovascular-disease\" class=\"medical medical_review\">C-reactive protein in cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiovascular-risk-of-smoking-and-benefits-of-smoking-cessation\" class=\"medical medical_review\">Cardiovascular risk of smoking and benefits of smoking cessation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=coronary-artery-endothelial-dysfunction-clinical-aspects\" class=\"medical medical_review\">Coronary artery endothelial dysfunction: Clinical aspects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=geriatric-health-maintenance\" class=\"medical medical_review\">Geriatric health maintenance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hdl-cholesterol-clinical-aspects-of-abnormal-values\" class=\"medical medical_review\">HDL cholesterol: Clinical aspects of abnormal values</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypertriglyceridemia\" class=\"medical medical_review\">Hypertriglyceridemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intracoronary-stent-restenosis\" class=\"medical medical_review\">Intracoronary stent restenosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=leukocyte-endothelial-adhesion-in-the-pathogenesis-of-inflammation\" class=\"medical medical_review\">Leukocyte-endothelial adhesion in the pathogenesis of inflammation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lipoprotein-classification-metabolism-and-role-in-atherosclerosis\" class=\"medical medical_review\">Lipoprotein classification, metabolism, and role in atherosclerosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lipoprotein-a-and-cardiovascular-disease\" class=\"medical medical_review\">Lipoprotein(a) and cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-elevated-low-density-lipoprotein-cholesterol-ldl-c-in-primary-prevention-of-cardiovascular-disease\" class=\"medical medical_review\">Management of elevated low density lipoprotein-cholesterol (LDL-C) in primary prevention of cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-low-density-lipoprotein-cholesterol-ldl-c-in-secondary-prevention-of-cardiovascular-disease\" class=\"medical medical_review\">Management of low density lipoprotein cholesterol (LDL-C) in secondary prevention of cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mechanisms-of-benefit-of-lipid-lowering-drugs-in-patients-with-coronary-heart-disease\" class=\"medical medical_review\">Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nutritional-antioxidants-in-coronary-heart-disease\" class=\"medical medical_review\">Nutritional antioxidants in coronary heart disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-established-risk-factors-for-cardiovascular-disease\" class=\"medical medical_review\">Overview of established risk factors for cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hemostasis\" class=\"medical medical_review\">Overview of hemostasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-possible-risk-factors-for-cardiovascular-disease\" class=\"medical medical_review\">Overview of possible risk factors for cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pcsk9-inhibitors-pharmacology-adverse-effects-and-use\" class=\"medical medical_review\">PCSK9 inhibitors: Pharmacology, adverse effects, and use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-and-risk-factors-for-cardiac-allograft-vasculopathy\" class=\"medical medical_review\">Pathogenesis of and risk factors for cardiac allograft vasculopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathology-and-pathogenesis-of-the-vulnerable-plaque\" class=\"medical medical_review\">Pathology and pathogenesis of the vulnerable plaque</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atherosclerosis-the-basics\" class=\"medical medical_basics\">Patient education: Atherosclerosis (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-cardiovascular-disease-events-in-those-with-established-disease-or-at-high-risk\" class=\"medical medical_review\">Prevention of cardiovascular disease events in those with established disease or at high risk</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-endothelin-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">Role of endothelin in heart failure with reduced ejection fraction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seasonal-influenza-vaccination-in-adults\" class=\"medical medical_review\">Seasonal influenza vaccination in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-role-of-the-vulnerable-plaque-in-acute-coronary-syndromes\" class=\"medical medical_review\">The role of the vulnerable plaque in acute coronary syndromes</a></li></ul></div></div>","javascript":null}